Phase I Trial of Concurrent Twice-Weekly Recombinant Human Interleukin-12 Plus Low-Dose IL-2 in Patients With Melanoma or Renal Cell Carcinoma
- 1 July 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (13) , 2564-2573
- https://doi.org/10.1200/jco.2003.12.119
Abstract
Purpose: To maintain interferon gamma (IFNγ) induction by recombinant human interleukin-12 (rhIL-12) and enhance its activity against melanoma and renal cell cancer, a regimen of twice-weekly intravenous (IV) rhIL-12 was modified to include concurrent low-dose subcutaneous (SC) IL-2 in a phase I dose escalation study.Keywords
This publication has 22 references indexed in Scilit:
- Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10AIDS, 2002
- IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapyJournal of Clinical Investigation, 2001
- Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.Journal of Clinical Investigation, 1998
- Tumor Cell Responses to IFNγ Affect Tumorigenicity and Response to IL-12 Therapy and AntiangiogenesisImmunity, 1998
- Requirement for V α 14 NKT Cells in IL-12-Mediated Rejection of TumorsScience, 1997
- Administration of Interleukin 12 With Pulse Interleukin 2 and the Rapid and Complete Eradication of Murine Renal CarcinomaJNCI Journal of the National Cancer Institute, 1996
- Inhibition of Angiogenesis In Vivo by Interleukin 12JNCI Journal of the National Cancer Institute, 1995
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive ImmunityAnnual Review of Immunology, 1995
- Antitumor and antimetastatic activity of interleukin 12 against murine tumors.The Journal of Experimental Medicine, 1993
- Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.The Journal of Experimental Medicine, 1992